Similarly, findings about the effect of EGFR inhibition on the immune cell infiltrate in these tumours have also displayed variability and remain to be conclusively established, with one study observing a decrease in regulatory T-cell (Tregs) levels after erlotinib therapy [14], whereas another did not notice any difference in tumour-infiltrating Tregs [15]. Here, EGFR is linked to neoplasm.